MacroGenics (MGNX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MGNX Stock Forecast

MacroGenics stock forecast is as follows: an average price target of $7.00 (represents a 120.13% upside from MGNX’s last price of $3.18) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.

MGNX Price Target

The average price target for MacroGenics (MGNX) is $7.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $5.00. This represents a potential 120.13% upside from MGNX's last price of $3.18.

MGNX Analyst Ratings

Hold

According to 10 Wall Street analysts, MacroGenics's rating consensus is 'Hold'. The analyst rating breakdown for MGNX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

MacroGenics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 07, 2024	Stephen Willey	Stifel Nicolaus	$6.00	$3.38	77.51%	88.68%
Jul 31, 2024	Silvan Tuerkcan	JMP Securities	$8.00	$5.25	52.38%	151.57%
Jul 31, 2024	Mayank Mamtani	B.Riley Financial	$5.00	$5.25	-4.76%	57.23%
Jul 29, 2024	Peter Lawson	Barclays	$9.00	$5.55	62.16%	183.02%
May 23, 2024	Kaveri Pohlman	BTIG	$9.00	$4.63	94.38%	183.02%
May 13, 2024	Debjit Chattopadhyay	H.C. Wainwright	$4.00	$4.38	-8.75%	25.79%
May 10, 2024	Peter Lawson	Barclays	$14.00	$14.67	-4.57%	340.25%
May 10, 2024	Etzer Darout	BMO Capital	$8.00	$14.67	-45.47%	151.57%
Apr 04, 2024	Stephen Willey	Stifel Nicolaus	$29.00	$13.67	112.14%	811.95%
Nov 22, 2022	Charles Zhu	Guggenheim	$12.00	$6.18	94.17%	277.36%
Jul 11, 2022	Kaveri Pohlman	BTIG	$6.00	$3.55	69.01%	88.68%
Jun 16, 2021	David Nierengarten	Wedbush	$32.00	$20.86	53.40%	906.29%

The latest MacroGenics stock forecast, released on Aug 07, 2024 by Stephen Willey from Stifel Nicolaus, set a price target of $6.00, which represents a 77.51% increase from the stock price at the time of the forecast ($3.38), and a 88.68% increase from MGNX last price ($3.18).

MacroGenics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	9
Avg Price Target	-	-	$10.22
Last Closing Price	$3.18	$3.18	$3.18
Upside/Downside	-100.00%	-100.00%	221.38%

In the current month, the average price target of MacroGenics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MacroGenics's last price of $3.18. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 18, 2024	JMP Securities	Market Perform	Market Perform	Hold
Sep 18, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Sep 16, 2024	Cowen & Co.	Hold	Hold	Hold
Aug 21, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Aug 15, 2024	JMP Securities	Market Perform	Market Perform	Hold
Jul 31, 2024	BTIG	Buy	Neutral	Downgrade
Jul 31, 2024	JMP Securities	Outperform	Outperform	Hold
Jul 31, 2024	Guggenheim	Accumulate	Neutral	Downgrade
Jul 31, 2024	B. Riley		Neutral	Downgrade
Jul 31, 2024	Guggenheim	Underperform	Accumulate	Downgrade
Jul 29, 2024	Barclays	Overweight	Overweight	Hold
May 23, 2024	BTIG	Buy	Buy	Hold
May 18, 2024	Citigroup	Buy	Buy	Hold
May 13, 2024	H.C. Wainwright	Neutral	Neutral	Hold
May 10, 2024	BMO Capital	Market Perform	Perform	Downgrade
May 10, 2024	Cowen & Co.	Buy	Hold	Downgrade
May 10, 2024	Barclays	Overweight	Overweight	Hold
May 10, 2024	BMO Capital	Outperform	Market Perform	Downgrade
Apr 09, 2024	Cowen & Co.		Buy	Upgrade
Apr 04, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Mar 04, 2024	BTIG	Buy	Buy	Hold
Feb 14, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Jan 24, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Jan 24, 2024	Guggenheim	Underperform	Underperform	Hold
Dec 20, 2023	Raymond James	Outperform	Outperform	Hold
Dec 20, 2023	Guggenheim	Buy	Buy	Hold
Nov 22, 2022	Guggenheim		Buy	Upgrade
Nov 14, 2022	BMO Capital	Perform	Outperform	Upgrade
Jul 12, 2022	BMO Capital		Perform	Downgrade
Jul 11, 2022	BTIG	Buy	Buy	Hold
Apr 26, 2022	Citigroup		Buy	Upgrade
Feb 25, 2022	SVB Leerink	Outperform	Outperform	Hold

MacroGenics's last stock rating was published by JMP Securities on Sep 18, 2024. The company gave MGNX a "Market Perform" rating, the same as its previous rate.

MacroGenics Financial Forecast

MacroGenics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	$11.00M	$10.40M	$13.14M	$24.21M	$71.18M	$41.73M	$26.01M	$10.67M	$13.62M	$15.58M	$30.37M	$16.88M	$52.69M	$18.25M	$20.26M	$13.68M	$25.19M	$18.74M	$10.59M	$9.66M	$4.70M	$2.06M
Avg Forecast	$17.11M	$24.21M	$10.90M	$11.93M	$29.31M	$87.61M	$20.94M	$14.86M	$32.63M	$50.90M	$29.19M	$96.19M	$64.37M	$29.28M	$14.16M	$23.18M	$22.83M	$34.01M	$32.15M	$26.20M	$26.01M	$14.04M	$10.90M	$9.48M	$13.28M	$15.26M	$14.45M	$18.80M	$3.78M	$1.85M
High Forecast	$31.24M	$44.20M	$19.90M	$18.30M	$37.95M	$87.71M	$20.94M	$27.13M	$45.90M	$51.73M	$53.30M	$175.60M	$117.52M	$29.28M	$14.16M	$23.18M	$22.83M	$34.01M	$32.15M	$26.20M	$26.01M	$14.04M	$10.90M	$9.48M	$13.28M	$15.26M	$14.45M	$18.80M	$4.54M	$2.21M
Low Forecast	$6.09M	$8.62M	$3.88M	$5.55M	$18.26M	$87.51M	$20.94M	$5.29M	$18.36M	$50.07M	$10.39M	$34.25M	$22.92M	$29.28M	$14.16M	$23.18M	$22.83M	$34.01M	$32.15M	$26.20M	$26.01M	$14.04M	$10.90M	$9.48M	$13.28M	$15.26M	$14.45M	$18.80M	$3.03M	$1.48M
# Analysts	1	1	1	3	6	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	10	16	8	11	7	11	7	7	17	8
Surprise %	-	-	-	-	-	-	-	-	0.34%	0.20%	0.45%	0.25%	1.11%	1.43%	1.84%	0.46%	0.60%	0.46%	0.94%	0.64%	2.03%	1.30%	1.86%	1.44%	1.90%	1.23%	0.73%	0.51%	1.24%	1.11%

MacroGenics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $14.86M, with a low forecast of $5.29M, and a high forecast of $27.13M. MGNX's average Quarter revenue forecast represents a 35.06% increase compared to the company's last Quarter revenue of $11.00M (Dec 23).

MacroGenics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	6	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	10	16	8	11	7	11	7	7	17	8
EBITDA	-	-	-	-	-	-	-	-	$-151.71M	$-35.50M	$-44.96M	$-37.35M	$15.21M	$-22.11M	$-38.93M	$-63.73M	$-55.07M	$-50.09M	$-37.15M	$-48.54M	$803.00K	$-33.08M	$-43.59M	$-41.91M	$-27.67M	$-41.99M	$-29.19M	$-42.11M	$-48.20M	$-35.68M
Avg Forecast	$-12.58M	$-17.80M	$-8.01M	$-8.77M	$-21.55M	$-64.41M	$-15.39M	$-41.33M	$-23.99M	$-37.42M	$-21.46M	$-44.21M	$-57.62M	$-28.11M	$-13.59M	$-47.28M	$-21.91M	$-32.65M	$-30.86M	$-28.01M	$-24.96M	$-13.48M	$-10.47M	$-46.44M	$-12.75M	$-14.65M	$-13.87M	$-35.75M	$-36.59M	$-31.63M
High Forecast	$-4.48M	$-6.34M	$-2.85M	$-4.08M	$-13.43M	$-64.33M	$-15.39M	$-33.07M	$-13.50M	$-36.81M	$-7.64M	$-35.36M	$-46.10M	$-28.11M	$-13.59M	$-37.82M	$-21.91M	$-32.65M	$-30.86M	$-22.41M	$-24.96M	$-13.48M	$-10.47M	$-37.15M	$-12.75M	$-14.65M	$-13.87M	$-28.60M	$-29.28M	$-25.30M
Low Forecast	$-22.97M	$-32.49M	$-14.63M	$-13.46M	$-27.90M	$-64.48M	$-15.39M	$-49.60M	$-33.75M	$-38.03M	$-39.18M	$-53.05M	$-69.15M	$-28.11M	$-13.59M	$-56.73M	$-21.91M	$-32.65M	$-30.86M	$-33.61M	$-24.96M	$-13.48M	$-10.47M	$-55.72M	$-12.75M	$-14.65M	$-13.87M	$-42.90M	$-43.91M	$-37.96M
Surprise %	-	-	-	-	-	-	-	-	6.32%	0.95%	2.09%	0.84%	-0.26%	0.79%	2.86%	1.35%	2.51%	1.53%	1.20%	1.73%	-0.03%	2.45%	4.16%	0.90%	2.17%	2.87%	2.10%	1.18%	1.32%	1.13%

3 analysts predict MGNX's average Quarter EBITDA for Mar 23 to be $-44.21M, with a high of $-35.36M and a low of $-53.05M. This is -390.56% lower than MacroGenics's previous annual EBITDA (Dec 22) of $15.21M.

MacroGenics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	6	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	10	16	8	11	7	11	7	7	17	8
Net Income	-	-	-	-	-	-	-	-	$-45.83M	$17.55M	$57.47M	$-38.25M	$12.80M	$-24.67M	$-40.80M	$-66.25M	$-58.02M	$-52.89M	$-39.94M	$-51.27M	$-2.09M	$-36.04M	$-46.88M	$-44.72M	$-30.40M	$-44.63M	$-31.77M	$-45.02M	$-49.54M	$-37.66M
Avg Forecast	$-30.59M	$-31.75M	$-46.52M	$-45.68M	$-23.25M	$13.30M	$-41.55M	$-43.23M	$-9.65M	$-5.99M	$-32.76M	$-46.23M	$-60.71M	$-24.04M	$-61.34M	$-49.45M	$-51.06M	$-44.52M	$-28.54M	$-29.59M	$-45.66M	$-58.32M	$-57.65M	$-49.55M	$-64.02M	$-62.27M	$-60.70M	$-38.21M	$-37.61M	$-33.38M
High Forecast	$-4.98M	$-5.17M	$-7.58M	$-34.26M	$-7.07M	$13.82M	$-6.77M	$-34.58M	$-5.57M	$-975.67K	$-5.33M	$-36.99M	$-48.57M	$-24.04M	$-61.34M	$-39.56M	$-51.06M	$-44.52M	$-28.54M	$-23.67M	$-45.66M	$-58.32M	$-57.65M	$-39.64M	$-64.02M	$-62.27M	$-60.70M	$-30.57M	$-30.09M	$-26.71M
Low Forecast	$-63.43M	$-65.82M	$-96.45M	$-57.10M	$-42.45M	$12.78M	$-86.14M	$-51.87M	$-13.73M	$-12.42M	$-67.91M	$-55.48M	$-72.85M	$-24.04M	$-61.34M	$-59.34M	$-51.06M	$-44.52M	$-28.54M	$-35.50M	$-45.66M	$-58.32M	$-57.65M	$-59.46M	$-64.02M	$-62.27M	$-60.70M	$-45.85M	$-45.13M	$-40.06M
Surprise %	-	-	-	-	-	-	-	-	4.75%	-2.93%	-1.75%	0.83%	-0.21%	1.03%	0.67%	1.34%	1.14%	1.19%	1.40%	1.73%	0.05%	0.62%	0.81%	0.90%	0.47%	0.72%	0.52%	1.18%	1.32%	1.13%

MacroGenics's average Quarter net income forecast for Dec 23 is $-9.65M, with a range of $-13.73M to $-5.57M. MGNX's average Quarter net income forecast represents a -154.96% decrease compared to the company's last Quarter net income of $17.55M (Sep 23).

MacroGenics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	6	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	10	16	8	11	7	11	7	7	17	8
SG&A	-	-	-	-	-	-	-	-	$12.56M	$12.41M	$13.69M	$13.53M	$13.67M	$15.36M	$13.67M	$16.25M	$15.58M	$17.16M	$15.23M	$15.04M	$12.56M	$9.73M	$10.22M	$10.23M	$11.89M	$11.83M	$12.12M	$10.22M	$9.23M	$7.46M
Avg Forecast	$11.26M	$15.93M	$7.17M	$7.85M	$19.28M	$57.63M	$13.77M	$10.57M	$21.47M	$33.48M	$19.21M	$11.31M	$16.31M	$19.26M	$9.32M	$12.10M	$15.02M	$22.38M	$21.15M	$8.68M	$17.11M	$9.24M	$7.17M	$6.24M	$8.74M	$10.04M	$9.50M	$8.67M	$2.49M	$1.21M
High Forecast	$20.55M	$29.08M	$13.09M	$12.04M	$24.97M	$57.70M	$13.77M	$12.69M	$30.20M	$34.03M	$35.06M	$13.57M	$19.57M	$19.26M	$9.32M	$14.51M	$15.02M	$22.38M	$21.15M	$10.41M	$17.11M	$9.24M	$7.17M	$6.24M	$8.74M	$10.04M	$9.50M	$10.41M	$2.99M	$1.46M
Low Forecast	$4.01M	$5.67M	$2.55M	$3.65M	$12.02M	$57.57M	$13.77M	$8.46M	$12.08M	$32.94M	$6.84M	$9.05M	$13.04M	$19.26M	$9.32M	$9.68M	$15.02M	$22.38M	$21.15M	$6.94M	$17.11M	$9.24M	$7.17M	$6.24M	$8.74M	$10.04M	$9.50M	$6.94M	$1.99M	$971.34K
Surprise %	-	-	-	-	-	-	-	-	0.59%	0.37%	0.71%	1.20%	0.84%	0.80%	1.47%	1.34%	1.04%	0.77%	0.72%	1.73%	0.73%	1.05%	1.42%	1.64%	1.36%	1.18%	1.28%	1.18%	3.71%	6.15%

MacroGenics's average Quarter SG&A projection for Mar 24 is $10.57M, based on 3 Wall Street analysts, with a range of $8.46M to $12.69M. The forecast indicates a -15.81% fall compared to MGNX last annual SG&A of $12.56M (Dec 23).

MacroGenics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	6	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	10	16	8	11	7	11	7	7	17	8
EPS	-	-	-	-	-	-	-	-	$-0.00	$0.28	-	$-0.62	$-1.55	$-0.40	$-0.66	$-1.08	$-0.95	$-0.86	$-0.66	$-0.90	$-0.04	$-0.66	$-0.94	$-0.91	$-0.62	$-0.91	$-0.65	$-0.99	$-1.34	$-1.08
Avg Forecast	$-0.49	$-0.51	$-0.74	$-0.73	$-0.37	$0.21	$-0.66	$-0.64	$-0.15	$-0.10	$-0.52	$0.45	$0.10	$-0.38	$-0.98	$-0.85	$-0.81	$-0.71	$-0.46	$-0.64	$-0.73	$-0.93	$-0.92	$-1.02	$-1.02	$-0.99	$-0.97	$-0.75	$-0.82	$-0.86
High Forecast	$-0.08	$-0.08	$-0.12	$-0.55	$-0.11	$0.22	$-0.11	$-0.10	$-0.09	$-0.02	$-0.08	$0.94	$0.21	$-0.38	$-0.98	$-0.85	$-0.81	$-0.71	$-0.46	$-0.64	$-0.73	$-0.93	$-0.92	$-1.02	$-1.02	$-0.99	$-0.97	$-0.75	$-0.66	$-0.69
Low Forecast	$-1.01	$-1.05	$-1.53	$-0.91	$-0.68	$0.20	$-1.37	$-1.33	$-0.22	$-0.20	$-1.08	$0.07	$0.02	$-0.38	$-0.98	$-0.85	$-0.81	$-0.71	$-0.46	$-0.64	$-0.73	$-0.93	$-0.92	$-1.02	$-1.02	$-0.99	$-0.97	$-0.75	$-0.98	$-1.03
Surprise %	-	-	-	-	-	-	-	-	0.00%	-2.94%	-0.00%	-1.37%	-15.18%	1.04%	0.67%	1.27%	1.17%	1.21%	1.45%	1.41%	0.05%	0.71%	1.02%	0.89%	0.61%	0.92%	0.67%	1.31%	1.63%	1.26%

According to 6 Wall Street analysts, MacroGenics's projected average Quarter EPS for Dec 23 is $-0.15, with a low estimate of $-0.22 and a high estimate of $-0.09. This represents a -154.81% decrease compared to MGNX previous annual EPS of $0.28 (Sep 23).

MacroGenics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
NKTX	Nkarta	$2.27	$21.60	851.54%	Buy
PEPG	PepGen	$4.30	$29.50	586.05%	Buy
MOLN	Molecular Partners	$5.25	$29.00	452.38%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
CCCC	C4 Therapeutics	$4.05	$20.00	393.83%	Buy
IPSC	Century Therapeutics	$1.17	$5.00	327.35%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
ANTX	AN2 Therapeutics	$1.34	$5.00	273.13%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
KZR	Kezar Life Sciences	$6.52	$17.50	168.40%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
PHVS	Pharvaris	$18.49	$42.00	127.15%	Buy
ZNTL	Zentalis Pharmaceuticals	$3.13	$7.00	123.64%	Buy
MGNX	MacroGenics	$3.34	$7.00	109.58%	Hold
TYRA	Tyra Biosciences	$15.22	$31.75	108.61%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
PTGX	Protagonist Therapeutics	$40.69	$57.33	40.89%	Buy

MGNX Forecast FAQ

Is MacroGenics a good buy?

No, according to 10 Wall Street analysts, MacroGenics (MGNX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 40.00% of MGNX's total ratings.

What is MGNX's price target?

MacroGenics (MGNX) average price target is $7 with a range of $5 to $9, implying a 120.13% from its last price of $3.18. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will MacroGenics stock go up soon?

According to Wall Street analysts' prediction for MGNX stock, the company can go up by 120.13% (from the last price of $3.18 to the average price target of $7), up by 183.02% based on the highest stock price target, and up by 57.23% based on the lowest stock price target.

Can MacroGenics stock reach $5?

MGNX's average twelve months analyst stock price target of $7 supports the claim that MacroGenics can reach $5 in the near future.

What are MacroGenics's analysts' financial forecasts?

MacroGenics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $152.72M (high $173.73M, low $132M), average EBITDA is $-143M (high $-126M, low $-157M), average net income is $-94.723M (high $-34.607M, low $-168M), average SG&A $101.26M (high $109.13M, low $91.81M), and average EPS is $-1.462 (high $-0.105, low $-3.175). MGNX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.15M (high $113.64M, low $24.14M), average EBITDA is $-47.158M (high $-17.747M, low $-83.546M), average net income is $-155M (high $-51.992M, low $-283M), average SG&A $42.2M (high $74.76M, low $15.88M), and average EPS is $-2.458 (high $-0.827, low $-4.499).

Did the MGNX's actual financial results beat the analysts' financial forecasts?

Based on MacroGenics's last annual report (Dec 2023), the company's revenue was $58.75M, which missed the average analysts forecast of $208.91M by -71.88%. Apple's EBITDA was $-168M, beating the average prediction of $-127M by 32.40%. The company's net income was $-9.058M, missing the average estimation of $-94.626M by -90.43%. Apple's SG&A was $52.19M, missing the average forecast of $85.47M by -38.94%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.317 by -99.97%. In terms of the last quarterly report (Dec 2023), MacroGenics's revenue was $11M, missing the average analysts' forecast of $32.63M by -66.28%. The company's EBITDA was $-152M, beating the average prediction of $-23.99M by 532.38%. MacroGenics's net income was $-45.833M, beating the average estimation of $-9.648M by 375.05%. The company's SG&A was $12.56M, missing the average forecast of $21.47M by -41.49%. Lastly, the company's EPS was $-0.0007, missing the average prediction of $-0.153 by -99.54%